Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | KDM6B | O15054 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18858141 | 0.89 | HDAC1 (0.47) | HDAC1HDAC3HDAC2 | |
| SCHEMBL18858135 | 0.87 | KDM4C (0.40) | KDM4CKDM6BKDM4D | |
| SCHEMBL18858143 | 0.81 | HDAC1 (0.35) | HDAC1HDAC3KDM4CKDM6BKDM4D | |
| SCHEMBL10206277 | 0.81 | CA1 (0.46) | HDAC1HDAC3HDAC2KDM4CKDM6B | |
| SCHEMBL27147974 | 0.79 | KDM4C (0.43) | HDAC1HDAC3HDAC2KDM4CKDM6B | |
| SCHEMBL18858136 | 0.76 | MAPK8 (0.39) | HDAC1HDAC3HDAC2KDM4CKDM6B | |
| SCHEMBL5767632 | 0.75 | NOTUM (0.57) | HDAC1HDAC3HDAC2 | |
| SCHEMBL9017891 | 0.73 | HDAC1 (0.49) | HDAC1HDAC3HDAC2KDM4CKDM6B | |
| SCHEMBL4075291 | 0.72 | NAMPT (0.42) | HDAC1 | |
| SCHEMBL14357917 | 0.72 | HDAC1 (0.46) | HDAC1HDAC3HDAC2KDM4CKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170135998-A1 | Aminopyridine Based Buffers with Wide Buffering Ranges, Antibiotics and Myelin Disease Therapy | TPAT IP LLC | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170135998-A1 | Aminopyridine Based Buffers with Wide Buffering Ranges, Antibiotics and Myelin Disease Therapy | AQP4, PMP22, MAG | HDAC1 2464/4885HDAC3 2650/4885HDAC2 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.